Opportunities for patients and the public to be involved in the work of the MHRA

AI Summary

The Medicines and Healthcare products Regulatory Agency (MHRA) has outlined its strategic commitment to integrating patient and public involvement into the UK’s regulatory processes. Guided by the Corporate Plan 2023-26 and the initial Patient Involvement Strategy launched in October 2021, the agency aims to ensure healthcare regulation reflects the lived experiences of those it serves. This initiative follows recommendations from the Independent Medicines and Medical Devices Safety Review to enhance transparency and public engagement. Key initiatives include the Rare Disease Consortium, which develops patient-focused frameworks for innovative therapies, and the Innovative Licensing and Access Pathway (ILAP). In 2025, ILAP incorporated twenty lay members to provide non-scientific perspectives on medicine applications. Additionally, the MHRA established the National Commission into the Regulation of AI in Healthcare to gather public evidence on emerging technologies. In October 2024, the agency transitioned to a new Patient and Public Community (PPC), replacing former consultative forums. This community serves as a central tool for meaningful engagement, allowing individuals and voluntary organizations to shape policy and decision-making. Members are expected to share lived experiences, champion safety, and maintain confidentiality. To participate, interested parties must submit an Expression of Interest form and adhere to the Working Together Agreement. The MHRA actively seeks a diverse membership base representing various medical conditions and perspectives to ensure that the regulatory framework remains inclusive and effective. This approach signifies a shift toward a more collaborative and patient-centered regulatory environment in the UK.